These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 16954467

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Computer modeling is no substitute for randomized clinical trials for decision making in early breast cancer hormonal therapy.
    Vakaet LA.
    J Clin Oncol; 2005 Nov 20; 23(33):8543-4; author reply 8546-7. PubMed ID: 16293887
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Criticism of tumor response criteria raises trial design questions.
    Twombly R.
    J Natl Cancer Inst; 2006 Feb 15; 98(4):232-4. PubMed ID: 16478740
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J.
    Stat Med; 2004 May 30; 23(10):1507-11. PubMed ID: 15122728
    [Abstract] [Full Text] [Related]

  • 27. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F, Reis-Filho JS.
    Int J Surg Pathol; 2009 Aug 30; 17(4):285-302. PubMed ID: 19103611
    [Abstract] [Full Text] [Related]

  • 28. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Hrushesky WJ, Retsky M, Baum M, Demicheli R.
    J Natl Cancer Inst; 2007 Jul 04; 99(13):1053; author reply 1053-4. PubMed ID: 17596578
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
    Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN.
    J Clin Oncol; 2008 Oct 01; 26(28):4679-83. PubMed ID: 18662965
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Personalized systemic treatment for breast cancer patients: is it a reality?
    Shimizu C, Fujiwara Y.
    Breast Cancer; 2008 Oct 01; 15(2):141-4. PubMed ID: 18274835
    [Abstract] [Full Text] [Related]

  • 34. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
    Chabner BA, Wittes R, Hoth D, Hubbard S.
    Public Health Rep; 1984 Oct 01; 99(4):355-60. PubMed ID: 6431482
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Loi S.
    Eur J Cancer; 2008 Dec 01; 44(18):2813-8. PubMed ID: 18990560
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Dec 01; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.